SKU: DPH122 | Published On: Jan 21 2021 | No. of Pages: 203 | Available Formats
The Global Neuroendocrine Tumor Treatment Market is expected to grow at a CAGR of 10.4% during the forecasting period (2020-2027).
The neuroendocrine tumor is a rare tumor that arises from the specialized body cells, called neuroendocrine cells. It may occur anywhere in the body but mostly occurs in the pancreas, digestive tract, lungs, rectum, and appendix. The neuroendocrine tumor can be either benign or malignant.
Source: DataM Intelligence Analysis (2019)
The major driving forces are the increasing prevalence of neuroendocrine carcinoma, technological advancements, rising awareness among people, and the growing number of government initiatives.
The prevalence of Neuroendocrine tumors is increasing across the globe, though being a rare disease as it is reported that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the US. Therefore the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment of this rare disease.
The presence of ongoing research and development activities is expected to drive the market growth. For instance, few ongoing clinical trials include RAD 001 to treat advanced midgut NETs, Lanreotide Autogel for non-functional tumors, and NET-01 chemotherapy for the pancreatic tumors. Also, ongoing R&D activities in detection techniques, like Ga labeled radionucleotide therapies and the radiofrequency ablation technique, are the key factors driving the demand market.
Below is one among the huge promising pipeline for neuroendocrine tumor treatment, which is expected to boost market growth.
Company |
Drug |
Indication |
Phase |
Anticipated launch |
Dana-Farber Cancer Institute in collaboration with Eli Lilly and Company |
Ramucirumab with Somatostatin Analog |
Carcinoid Tumors |
Phase 2 |
2023 |
The presence of increasing investments by government organizations is expected to drive the market growth. For instance, organizations, such as the Neuroendocrine Tumor Research Foundation (NETRF), has invested more than 1.5 USD million in the development of advanced radiation therapy called Peptide Receptor Radionuclide Therapy (PRRT).
Rising awareness is expected to accelerate market growth over the forecast period. For instance, several organizations across the world are conducting national and international programs to increase awareness about the neuroendocrine tumors for early diagnosis of the disease. For instance, the International Neuroendocrine Cancer Alliance observes the neuroendocrine day on November 10, every year. Such awareness programs also help vendors to understand opportunities in the current market scenario and invest in research to develop new therapies.
However, the high cost of development and the onset of side effects are expected to hinder the market growth.
The onset of side effects is likely to hamper the growth of the market over the forecast period. The possible side effects include high blood sugars, the development of gallstones, and mild digestive system upset, such as bloating and nausea.
By therapy type, the neuroendocrine tumor treatment market can be segmented into somatostatin analogs (SSAs), targeted therapy, and others.
The Somatostatin product segment is expected to propel the market growth over the forecast period, owing to the safe treatment procedure offered by SSA. SSAs are usually used to treat patients who are resistant to surgery and radiation therapy. Many somatostatin analogs are currently under clinical trials and waiting for approval. For instance,
Company/Organization |
Drug |
Study Title |
Phase |
Anticipated launch |
Tarveda Therapeutics |
PEN-221 |
PEN-221 in somatostatin receptor 2 expressing advanced cancers including neuroendocrine and small cell lung cancers |
Phase 1/2a |
2020 |
University Health Network, Toronto |
Lutetium-177 Octreotate |
Patients with 68Ga-DOTATATE somatostatin receptor-positive neuroendocrine tumor |
- |
2024 |
Universitaire Ziekenhuizen Leuven |
Al18F-NOTA-octreotide |
Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors |
Phase 1 |
December 2019 |
The targeted therapy segment is expected to grow at a significant rate over the forecast period, owing to the presence of FDA approved drugs. For instance, in February 2016, Everolimus (Afinitor), a targeted therapy approved by the US FDA for the treatment of advanced NETs of the lung, GI tract, and pancreas. This drug can help to slow down the growth of these tumors in some patients, but it does not usually shrink tumors. Another targeted therapy, sunitinib (Sutent), which targets a protein called VEGF, is also approved by the US FDA for the treatment of pancreatic NETs. Thus, the presence of FDA approved drugs for neuroendocrine tumor treatment is driving the market.
Source: DataM Intelligence Analysis (2019)
By indication, the neuroendocrine tumor treatment market can be segmented into the small intestine, lungs, pancreas, gastrointestinal, and others.
The small intestine segment is expected to grow at a high rate over the forecast period, as the GI tract is more prone to develop NETs. As per the statistics published in the investor presentation of Novartis AG, GI comprised 61% of the total NETs, and among them, tumors in the small intestine were the most common ones.
The pancreas segment is expected to grow at a high rate over the forecast period, owing to the increasing R&D investments for the development of novel therapies for pancreatic NETs. For instance,
Company/Organization |
Indication |
Anticipated launch |
Hutchison Medipharma Limited |
For the treatment of advanced pancreatic neuroendocrine tumor |
2020 |
University Hospital, Strasbourg, France |
Clinicopathological assessment of pancreatic neuroendocrine tumors and carcinomas in the Alsace region |
2020 |
By route of administration, the neuroendocrine tumor treatment market can be segmented into oral and parenteral.
The oral segment is expected to grow at a high rate over the forecast period, owing to the presence of FDA approved oral drugs. For instance, in February 2017, the FDA approved Xermelo (telotristat ethyl), in combination with a somatostatin analog. It is an oral drug that reduces the overproduction of seratonin that some NETs cause and, in so doing, relieves diarrhea.
Geographically, the global neuroendocrine tumor treatment market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is dominating the global neuroendocrine tumor treatment market in 2018 and is estimated to hold significant market size over the forecast period (2020-2027) owing to supportive insurance policies in the region facilitating NET treatment, like Medicare, Medicaid, and Tricare. Also, sophisticated healthcare facilities and high R&D expenditure by pharmaceutical companies and regional government for cancer research are other factors driving the market.
The increasing prevalence of neuroendocrine cancer is expected to drive market growth over the forecast period. For instance, according to the statistics published by the American Society of Clinical Oncology (ASCO), in 2016, around 8,000 adults in the US were diagnosed with GI tract-carcinoid tumors. Also, as per Cancer.Net, it is estimated that more than 12,000 people in the US are diagnosed with a NET every year, and approximately 170,000 people are living with 1. This increasing prevalence of neuroendocrine tumors in the GI tract is expected to drive the market.
Also, the presence of ongoing research activities by several organizations is expected to drive the market growth over the forecast period.
Company/Organization |
Drug/Test |
Indication |
Phase |
Anticipated launch |
University Health Network, Toronto |
68Ga -DOTATATE PET scans |
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors |
- |
2024 |
National Cancer Institute (NCI) National Institutes of Health (NIH) |
Gallium 68 Pentixafor |
neuroendocrine tumors |
Early Phase 1 |
2020 |
Source: DataM Intelligence Analysis (2019)
The major players operating in the global neuroendocrine tumor treatment market are Amgen, Inc, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen Pharmaceuticals, Novartis AG, Hutchinson Medipharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, and Pfizer Inc.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the neuroendocrine tumor treatment market globally. For instance,
On July 30, 2018, Progenics Pharmaceuticals, Inc. announced that the US FDA had approved the New Drug Application for AZEDRA (iobenguane I 131) injection for the treatment of pheochromocytoma or paraganglioma who require systemic anticancer therapy.
On July 12, 2018, Novartis launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor (NET) community.
In January 2018, Novartis AG received FDA approval for Luthatera, radiolabelled somatostatin analog for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
In October 2017, Novartis announced the acquisition of Advanced Accelerator Applications, a radiopharmaceutical company, to expand its oncology product portfolio.
In February 2016, Novartis received FDA approval for Afinitor for the treatment of both GI and lung neuroendocrine tumors.
The Global Neuroendocrine Tumor Treatment Market report would provide access to an approx, 72 market data tables, 63 figures, and 220 pages.
Related Reports:
Gastrointestinal Stromal Tumor (GIST) – Pipeline Insights
List of Tables
TABLE 01 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2018, 2022 & 2027 ($ MILLION)
TABLE 02 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2018, 2022 & 2027 ($ MILLION)
TABLE 03 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)
TABLE 04 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)
TABLE 05 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)
TABLE 06 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2018, 2022 & 2027 ($ MILLION)
TABLE 07 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 08 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2018, 2022 & 2027 ($ MILLION)
TABLE 09 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 10 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2017-2027 ($ MILLION)
TABLE 11 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2017-2027 ($ MILLION)
TABLE 12 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)
TABLE 13 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 14 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)
TABLE 15 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 16 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)
TABLE 17 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 18 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 19 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 20 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 21 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 22 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 23 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 24 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 25 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 26 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 27 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 28 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 29 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 30 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 31 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 32 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 33 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 34 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 35 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 36 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 37 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 38 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)
TABLE 39 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)
TABLE 40 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)
TABLE 41 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)
TABLE 42 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)
TABLE 43 AMGEN, INC: OVERVIEW
TABLE 44 AMGEN, INC: PRODUCT PORTFOLIO
TABLE 45 AMGEN, INC: KEY DEVELOPMENTS
TABLE 46 BRISTOL-MYERS SQUIBB: OVERVIEW
TABLE 47 BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 48 BRISTOL-MYERS SQUIBB: KEY DEVELOPMENTS
TABLE 49 ELI LILLY & COMPANY: OVERVIEW
TABLE 50 ELI LILLY & COMPANY: PRODUCT PORTFOLIO
TABLE 51 ELI LILLY & COMPANY: KEY DEVELOPMENTS
TABLE 52 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW
TABLE 53 F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 54 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS
TABLE 55 IPSEN PHARMACEUTICALS: OVERVIEW
TABLE 56 IPSEN PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 57 IPSEN PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 58 NOVARTIS AG: OVERVIEW
TABLE 59 NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 60 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 61 PFIZER INC: OVERVIEW
TABLE 62 PFIZER INC: PRODUCT PORTFOLIO
TABLE 63 PFIZER INC: KEY DEVELOPMENTS
TABLE 64 HUTCHINSON MEDIPHARMA LIMITED: OVERVIEW
TABLE 65 HUTCHINSON MEDIPHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 66 HUTCHINSON MEDIPHARMA LIMITED: KEY DEVELOPMENTS
TABLE 67 TARVEDA THERAPEUTICS: OVERVIEW
TABLE 68 TARVEDA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 69 TARVEDA THERAPEUTICS: KEY DEVELOPMENTS
TABLE 70 PROGENICS PHARMACEUTICALS: OVERVIEW
TABLE 71 PROGENICS PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 72 PROGENICS PHARMACEUTICALS: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 01 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 02 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 03 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)
FIGURE 04 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 05 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 06 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 07 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 08 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY THERAPY TYPE, 2018-2027 (%)
FIGURE 09 SOMATOSTATIN ANALOGS (SSAS): GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 10 TARGETED THERAPY: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 11 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 12 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY INDICATION, 2018-2027 (%)
FIGURE 13 SMALL INTESTINE: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 14 LUNGS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 15 PANCREAS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 16 GASTROINTESTINAL: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 17 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 18 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY END-USER, 2018-2027 (%)
FIGURE 19 HOSPITALS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 20 CLINICS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 21 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 22 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY REGION, 2018-2027 (%)
FIGURE 23 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2027 (%)
FIGURE 24 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 25 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 26 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 27 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 28 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 29 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 30 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 31 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 32 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 33 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 34 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 35 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 36 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 37 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 38 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 39 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 40 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 41 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 42 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 43 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 44 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 45 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 46 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 47 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 48 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION)
FIGURE 49 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%)
FIGURE 50 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)
FIGURE 51 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%)
FIGURE 52 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%)
FIGURE 53 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%)
FIGURE 54 AMGEN, INC: FINANCIALS
FIGURE 55 BRISTOL-MYERS SQUIBB: FINANCIALS
FIGURE 56 ELI LILLY & COMPANY: FINANCIALS
FIGURE 57 F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
FIGURE 58 IPSEN PHARMACEUTICALS: FINANCIALS
FIGURE 59 NOVARTIS AG: FINANCIALS
FIGURE 60 PFIZER INC: FINANCIALS
FIGURE 61 HUTCHINSON MEDI PHARMA LIMITED: FINANCIALS
FIGURE 62 TARVEDA THERAPEUTICS: FINANCIALS
FIGURE 63 PROGENICS PHARMACEUTICALS: FINANCIALS
Get your FREE SAMPLE PROPOSAL with a single click!